FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3085665632> ?p ?o ?g. }

• W3085665632 endingPage "2206" @default.
• W3085665632 startingPage "2199" @default.
• W3085665632 abstract "Introduction Ensifentrine is an inhaled first-in-class dual inhibitor of phosphodiesterase (PDE) 3 and 4. In a four-week randomized, double-blind, placebo-controlled, parallel-group study in patients with chronic obstructive pulmonary disease (COPD), nebulized ensifentrine 0.75 to 6mg twice daily significantly improved bronchodilation and symptoms, with all doses being well tolerated. Here, we report data for a number of prespecified exploratory and post hoc endpoints from this study that help to further profile the effect of ensifentrine on symptoms. Methods Eligible patients were males or females aged 40-75 years with COPD, post-bronchodilator forced expiratory volume in 1 second 40-80% predicted. Other than being clinically stable for at least four weeks prior to entry, there were no symptomatic inclusion or exclusion criteria. The outcome measures reported in this manuscript are the Evaluating Respiratory Symptoms [E-RS™:COPD] questionnaire total score and subscales (breathlessness, cough/sputum and chest symptoms) at Weeks 1-4, Transition Dyspnea Index (TDI) focal score at Weeks 2 and 4, and St George's Respiratory Questionnaire - COPD Specific (SGRQ-C) total score and domain data (symptoms, activity and impacts) at Week 4. Results There was a gradual improvement versus placebo with all ensifentrine doses for all three E-RS™:COPD subscales from Week 1 to Week 4, with the greatest ensifentrine effect on the breathlessness subscale, and all four doses superior to placebo from Week 2 onwards (p<0.05). For TDI focal score, all ensifentrine doses were superior to placebo at Weeks 2 and 4 (p<0.05). In the individual SGRQ-C domains at Week 4, ensifentrine had the greatest effect on the symptoms domain, with ensifentrine 6mg superior to placebo (p<0.05). Conclusion In these analyses, ensifentrine demonstrated a notable early and meaningful effect on dyspnea, with this effect observed across two different assessment tools." @default.
• W3085665632 created "2020-09-21" @default.
• W3085665632 creator A5068917661 @default.
• W3085665632 creator A5078664755 @default.
• W3085665632 creator A5087999170 @default.
• W3085665632 creator A5090134623 @default.
• W3085665632 creator A5091515666 @default.
• W3085665632 date "2020-09-01" @default.
• W3085665632 modified "2023-09-24" @default.
• W3085665632 title "<p>Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD – A Detailed Analysis</p>" @default.
• W3085665632 cites W1995135796 @default.
• W3085665632 cites W2044624199 @default.
• W3085665632 cites W2049610222 @default.
• W3085665632 cites W2109143421 @default.
• W3085665632 cites W2112433656 @default.
• W3085665632 cites W2125373114 @default.
• W3085665632 cites W2141402647 @default.
• W3085665632 cites W2149978091 @default.
• W3085665632 cites W2155122370 @default.
• W3085665632 cites W2162689366 @default.
• W3085665632 cites W2301817671 @default.
• W3085665632 cites W2302395399 @default.
• W3085665632 cites W2396947503 @default.
• W3085665632 cites W2513201803 @default.
• W3085665632 cites W2599380139 @default.
• W3085665632 cites W2889533372 @default.
• W3085665632 cites W2949271607 @default.
• W3085665632 cites W3008746762 @default.
• W3085665632 doi "https://doi.org/10.2147/copd.s263025" @default.
• W3085665632 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7502392" @default.
• W3085665632 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32982212" @default.
• W3085665632 hasPublicationYear "2020" @default.
• W3085665632 type Work @default.
• W3085665632 sameAs 3085665632 @default.
• W3085665632 citedByCount "8" @default.
• W3085665632 countsByYear W30856656322021 @default.
• W3085665632 countsByYear W30856656322022 @default.
• W3085665632 countsByYear W30856656322023 @default.
• W3085665632 crossrefType "journal-article" @default.
• W3085665632 hasAuthorship W3085665632A5068917661 @default.
• W3085665632 hasAuthorship W3085665632A5078664755 @default.
• W3085665632 hasAuthorship W3085665632A5087999170 @default.
• W3085665632 hasAuthorship W3085665632A5090134623 @default.
• W3085665632 hasAuthorship W3085665632A5091515666 @default.
• W3085665632 hasBestOaLocation W30856656321 @default.
• W3085665632 hasConcept C126322002 @default.
• W3085665632 hasConcept C181199279 @default.
• W3085665632 hasConcept C185592680 @default.
• W3085665632 hasConcept C2776780178 @default.
• W3085665632 hasConcept C2778926808 @default.
• W3085665632 hasConcept C55493867 @default.
• W3085665632 hasConcept C62826618 @default.
• W3085665632 hasConcept C71924100 @default.
• W3085665632 hasConcept C90924648 @default.
• W3085665632 hasConceptScore W3085665632C126322002 @default.
• W3085665632 hasConceptScore W3085665632C181199279 @default.
• W3085665632 hasConceptScore W3085665632C185592680 @default.
• W3085665632 hasConceptScore W3085665632C2776780178 @default.
• W3085665632 hasConceptScore W3085665632C2778926808 @default.
• W3085665632 hasConceptScore W3085665632C55493867 @default.
• W3085665632 hasConceptScore W3085665632C62826618 @default.
• W3085665632 hasConceptScore W3085665632C71924100 @default.
• W3085665632 hasConceptScore W3085665632C90924648 @default.
• W3085665632 hasLocation W30856656321 @default.
• W3085665632 hasLocation W30856656322 @default.
• W3085665632 hasOpenAccess W3085665632 @default.
• W3085665632 hasPrimaryLocation W30856656321 @default.
• W3085665632 hasRelatedWork W1990017958 @default.
• W3085665632 hasRelatedWork W1990051268 @default.
• W3085665632 hasRelatedWork W2126482145 @default.
• W3085665632 hasRelatedWork W2141323574 @default.
• W3085665632 hasRelatedWork W2167884992 @default.
• W3085665632 hasRelatedWork W2343709048 @default.
• W3085665632 hasRelatedWork W2597908783 @default.
• W3085665632 hasRelatedWork W2796776231 @default.
• W3085665632 hasRelatedWork W3092457805 @default.
• W3085665632 hasRelatedWork W1873688680 @default.
• W3085665632 hasVolume "Volume 15" @default.
• W3085665632 isParatext "false" @default.
• W3085665632 isRetracted "false" @default.
• W3085665632 magId "3085665632" @default.
• W3085665632 workType "article" @default.